Scarica l'app Stockscreener
17.50
0.40%
-0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 30, 2026 - biospace.com
Sarepta Therapeutics Is Maintained at Neutral by JP Morgan - Moomoo
Sarepta Therapeutics stock falls 1.28 percent as DMD data land - AD HOC NEWS
Sarepta Reports ELEVIDYS Duchenne Trial Data - grafa.com
Sarepta Therapeutics (SRPT) Reports Positive Functional Data for Older Duchenne Muscular Dystrophy Patients - GuruFocus
Sarepta presents Elevidys data in older Duchenne patients - Investing.com
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne - Sarepta Therapeutics
Operating cash flow per share of Sarepta Therapeutics, Inc. – HAN:AB3A - TradingView
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
Liquidity Mapping Around (SRPT) Price Events - Stock Traders Daily
SRPT Reiterates by Needham -- Maintains Underperform Rating - GuruFocus
Sarepta Therapeutics, Inc. Revenue Breakdown – LS:A1J1BH - TradingView
Why Sarepta Therapeutics (SRPT) Is Down 7.2% After AAVrh74 Patent Peace With REGENXBIO And UPenn - Yahoo Finance
SRPT Should I Buy - Intellectia AI
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress - BioSpace
Regenxbio stock gains on positive gene therapy trial data By Investing.com - Investing.com UK
Sarepta Settles Regenxbio’s Patent Infringement Claims in $39M Deal - GenomeWeb
Jefferies reiterates Sarepta Therapeutics stock rating on pipeline potential By Investing.com - Investing.com Canada
Sarepta to pay Regenxbio $39M to settle gene therapy claims; Vida eyes fourth fund - Endpoints News
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting - BioSpace
Sarepta to present gene therapy data at neuromuscular meeting - Investing.com
Sarepta to present gene therapy data at neuromuscular meeting By Investing.com - Investing.com Canada
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27 - Business Wire
Sarepta Therapeutics, Inc. (SRPT.MX) Stock Forum & Discussion - Yahoo! Finance Canada
Morgan Stanley Views Sarepta CEO Transition As A ‘Positive’ – So, Why Is It Cautious On SRPT Stock In The Near Term? - stocktwits.com
This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally Next - Stocktwits
REGENXBIO and Sarepta Resolve ELEVIDYS Patent Litigation with $39 Million Settlement - Kalkine Media
Sarepta Therapeutics, Inc. (SRPT) Stock Forecasts - Yahoo Finance
Sarepta Resolves AAVrh74 Gene Therapy Patent Dispute - TipRanks
Sarepta Therapeutics Drops 7.1% Amid Sector-Wide Selling - AlphaStreet
SRPT Looks 81.5% Undervalued on GF Value™ Amid Rare Disease Tria - GuruFocus
Sarepta Therapeutics stock gains analyst support after mixed rating signals - AD HOC NEWS
Sarepta Therapeutics stock holds near USD 19.76 after analyst reset - AD HOC NEWS
Sarepta Therapeutics, Inc. (SRPT) Stock forecasts - Yahoo Finance UK
Price-Driven Insight from (SRPT) for Rule-Based Strategy - Stock Traders Daily
Demand Stabilization Might Change The Case For Investing In Sarepta Stock (SRPT) - simplywall.st
Massachusetts Judge Bars Sarepta Therapeutics Investor Suit Over Alleged Risk Misstatements - Lawxy AI
Sarepta Bats Away Investors’ Duchenne Therapy Safety Lawsuit (1) - Bloomberg Law News
Sarepta Therapeutics, Inc.Common Stock (NQ: SRPT - The Chronicle-Journal
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near - Yahoo Finance
Transcript : Sarepta Therapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 08:30 AM - marketscreener.com
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
Sarepta Therapeutics Drops 5.5% Amid Sector-Wide Selling - AlphaStreet
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits
SRPT Looks 79.1% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Sarepta Therapeutics climbs 10%, rebounding from recent slide (SRPT:NASDAQ) - Seeking Alpha
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving High - Benzinga
H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target By Investing.com - Investing.com Canada
Sarepta (NASDAQ: SRPT) CFO now holds 121,792 shares after tax withholding - Stock Titan
Tax on stock award trims Sarepta (NASDAQ: SRPT) EVP stake to 115,519 shares - Stock Titan
Sarepta (SRPT) COO reports tax share withholding after RSU vesting - Stock Titan
Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook By Investing.com - Investing.com South Africa
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook - Investing.com India
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower - Benzinga
Mizuho reiterates Sarepta stock rating after Novartis trial miss By Investing.com - Investing.com South Africa
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year - BioSpace
Why is Sarepta Therapeutics stock sliding today? By Investing.com - Investing.com Canada
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):